AU2019247838A1 - Compositions and methods for treating renal injury - Google Patents

Compositions and methods for treating renal injury Download PDF

Info

Publication number
AU2019247838A1
AU2019247838A1 AU2019247838A AU2019247838A AU2019247838A1 AU 2019247838 A1 AU2019247838 A1 AU 2019247838A1 AU 2019247838 A AU2019247838 A AU 2019247838A AU 2019247838 A AU2019247838 A AU 2019247838A AU 2019247838 A1 AU2019247838 A1 AU 2019247838A1
Authority
AU
Australia
Prior art keywords
renal
alkyl
group
pgdh
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019247838A
Other languages
English (en)
Inventor
Ki Beom Bae
Hye Jung Kim
Sun-Hee Kim
Sanford Markowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Publication of AU2019247838A1 publication Critical patent/AU2019247838A1/en
Priority to AU2025201403A priority Critical patent/AU2025201403A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019247838A 2018-04-04 2019-04-04 Compositions and methods for treating renal injury Abandoned AU2019247838A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025201403A AU2025201403A1 (en) 2018-04-04 2025-02-27 Compositions and methods for treating renal injury

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652769P 2018-04-04 2018-04-04
US62/652,769 2018-04-04
PCT/US2019/025812 WO2019195565A1 (en) 2018-04-04 2019-04-04 Compositions and methods for treating renal injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025201403A Division AU2025201403A1 (en) 2018-04-04 2025-02-27 Compositions and methods for treating renal injury

Publications (1)

Publication Number Publication Date
AU2019247838A1 true AU2019247838A1 (en) 2020-10-15

Family

ID=68101395

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019247838A Abandoned AU2019247838A1 (en) 2018-04-04 2019-04-04 Compositions and methods for treating renal injury
AU2025201403A Pending AU2025201403A1 (en) 2018-04-04 2025-02-27 Compositions and methods for treating renal injury

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025201403A Pending AU2025201403A1 (en) 2018-04-04 2025-02-27 Compositions and methods for treating renal injury

Country Status (7)

Country Link
US (3) US20210100779A1 (https=)
EP (1) EP3781154A4 (https=)
JP (1) JP7426941B2 (https=)
CN (1) CN112739344A (https=)
AU (2) AU2019247838A1 (https=)
CA (1) CA3095308A1 (https=)
WO (1) WO2019195565A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230011910A (ko) * 2020-02-21 2023-01-25 케이스 웨스턴 리저브 유니버시티 신장 손상을 치료하기 위한 조성물 및 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187221A1 (en) * 2003-09-08 2005-08-25 Japan Tobacco Inc. Method of treating ischemia reperfusion injury
DK2838533T3 (da) * 2012-04-16 2017-11-27 Univ Case Western Reserve Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
JP2018511616A (ja) * 2015-04-14 2018-04-26 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity

Also Published As

Publication number Publication date
JP2021519797A (ja) 2021-08-12
EP3781154A4 (en) 2022-02-23
JP7426941B2 (ja) 2024-02-02
AU2025201403A1 (en) 2025-03-20
US20240024297A1 (en) 2024-01-25
US20210100779A1 (en) 2021-04-08
CA3095308A1 (en) 2019-10-10
EP3781154A1 (en) 2021-02-24
CN112739344A (zh) 2021-04-30
US20250325524A1 (en) 2025-10-23
WO2019195565A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
US20250325524A1 (en) Compositions and methods for treating renal injury
US20230052363A1 (en) Compositions and methods for treating renal injury
US20230310390A1 (en) Inhibitors of short-chain dehydrogenase activity for treating neurodegeneration
JP2016534069A (ja) Ｈｄａｃ６阻害剤での多嚢胞性疾患の治療
JP2007509968A (ja) 新形成を治療または予防するためのｈｓｐ９０阻害剤およびホスホジエステラーゼ阻害剤を含む組み合わせ
EP4326263A1 (en) Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
WO2019010482A1 (en) COMPOSITIONS AND METHODS FOR MODULATING COLUMN MATURATION
US20240366568A1 (en) Compositions and methods for treating tissue injury
US20240279201A1 (en) Dual wnt signaling pathway inhibitors and ampk activators for treatments of disease
US11046657B2 (en) Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines
JP2005526768A (ja) 炎症関連遺伝子を調節するデキサナビノール及びデキサナビノール類似体
JP2008545735A (ja) Ｓｈｐ−２阻害剤、それらを含む薬剤組成物及びホスファターゼ媒介性疾患を治療するためのその使用
CN106164059A (zh) 用天冬酰胺内肽酶（aep）抑制剂以及相关组合物对神经退行性疾病的治疗
AU2011312333A1 (en) Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity
HK40052492A (en) Compositions and methods for treating renal injury
JP2004099560A (ja) 薬剤性腎障害の予防及び／又は治療のための医薬
WO2014012000A2 (en) No-releasing guanidine-coxib anti-cancer agents
US20080090788A1 (en) Chemical Compounds
RU2797677C2 (ru) Модуляторы альфа-синуклеина
WO2026074529A1 (en) Sephin1 and related compound therapy
JP2026503263A (ja) 腎線維症等の疾患の治療又は予防における化合物１の使用
WO2025240868A1 (en) Method of using chemically stable keto-amide fibroblast activation protein-targeted conjugates and compositions comprising same to treat fibrosis
CN117545480A (zh) 作为赖氨酰氧化酶的抑制剂的双噻唑衍生物

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted